1. Home
  2. IMUX vs PDSB Comparison

IMUX vs PDSB Comparison

Compare IMUX & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • PDSB
  • Stock Information
  • Founded
  • IMUX 2016
  • PDSB 2005
  • Country
  • IMUX United States
  • PDSB United States
  • Employees
  • IMUX N/A
  • PDSB N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • PDSB Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • PDSB Health Care
  • Exchange
  • IMUX Nasdaq
  • PDSB Nasdaq
  • Market Cap
  • IMUX 67.8M
  • PDSB 72.2M
  • IPO Year
  • IMUX N/A
  • PDSB N/A
  • Fundamental
  • Price
  • IMUX $0.70
  • PDSB $1.28
  • Analyst Decision
  • IMUX Strong Buy
  • PDSB Strong Buy
  • Analyst Count
  • IMUX 6
  • PDSB 2
  • Target Price
  • IMUX $11.60
  • PDSB $10.00
  • AVG Volume (30 Days)
  • IMUX 2.6M
  • PDSB 565.2K
  • Earning Date
  • IMUX 08-07-2025
  • PDSB 08-12-2025
  • Dividend Yield
  • IMUX N/A
  • PDSB N/A
  • EPS Growth
  • IMUX N/A
  • PDSB N/A
  • EPS
  • IMUX N/A
  • PDSB N/A
  • Revenue
  • IMUX N/A
  • PDSB N/A
  • Revenue This Year
  • IMUX N/A
  • PDSB N/A
  • Revenue Next Year
  • IMUX N/A
  • PDSB N/A
  • P/E Ratio
  • IMUX N/A
  • PDSB N/A
  • Revenue Growth
  • IMUX N/A
  • PDSB N/A
  • 52 Week Low
  • IMUX $0.56
  • PDSB $0.85
  • 52 Week High
  • IMUX $2.11
  • PDSB $4.42
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 35.71
  • PDSB 36.81
  • Support Level
  • IMUX $0.68
  • PDSB $1.54
  • Resistance Level
  • IMUX $0.75
  • PDSB $1.66
  • Average True Range (ATR)
  • IMUX 0.06
  • PDSB 0.12
  • MACD
  • IMUX -0.00
  • PDSB -0.05
  • Stochastic Oscillator
  • IMUX 10.40
  • PDSB 0.81

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Share on Social Networks: